Faeth Therapeutics Q2 FY26 net loss widens to $16.01 million

Reuters2026/08/04 11:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Faeth Therapeutics posted a net loss of $16.01 million, or $2.84 per share, for the quarter ended June 30, 2026.
R&D expense more than doubled to $9.18 million; G&A expense more than doubled to $9.21 million.
Cash, cash equivalents, and marketable securities climbed to $186.4 million as of June 30, 2026.
First patient dosed in the Phase 1b/2 PIK-101 trial in HR+/HER2- advanced breast cancer in April.
Topline data from the Phase 2 PIK-201 endometrial cancer trial expected by year-end; initial PIK-101 safety and efficacy data expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260804105795) on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Faeth Therapeutics Q2 FY26 net loss widens to $16.01 million

You may also like

Crypto prices